Effect of oral sodium bicarbonate supplementation on progression of chronickidney disease in patients with chronic metabolic acidosis: study protocol for arandomized controlled trial (SoBic-Study)

Trials

Gere Sunder-Plassmann²  Walter H Hörl²  Alice Schmidt²  Melanie Fraunschiel³  Georg Heinze¹  Max Plischke²  Daniel Cejka²  Martina Gaggl² 

[1] Center of Medical Statistics, Informatics and Intelligent Systems, Section ofClinical Biometrics, Medical University of Vienna, Vienna, Austria;Department of Medicine III, Division of Nephrology and Dialysis, MedicalUniversity of Vienna, Vienna, Austria;Center of Medical Statistics, Informatics and Intelligent Systems, Sectionfor Medical Information Management and Imaging, Medical University ofVienna, Vienna, Austria

关键词: Progression;    Acidotic;    Acid retention;    Acid–base balance;    Sodium bicarbonate;    Kidney injury;    Chronic kidney disease;    Metabolic acidosis;   

Others  :  1093553
DOI  :  10.1186/1745-6215-14-196

 received in 2012-11-28, accepted in 2013-06-17,  发布年份 2013

【 摘 要 】

Background

Overt chronic metabolic acidosis in patients with chronic kidney disease develops after a drop of glomerular filtration rate to less than approximately 25 mL/min/1.73 m². The pathogenic mechanism seems to be a lack of tubular bicarbonate production, which in healthy individuals neutralizes the acid net production. As shown in several animal and human studies the acidotic milieu alters bone and vitamin D metabolism, induces muscle wasting, and impairs albumin synthesis, aside from a direct alteration of renal tissue by increasing angiotensin II, aldosteron and endothelin kidney levels. Subsequent studies testing various therapeutic approaches in very selected study populations showed that oral supplementation of the lacking bicarbonate halts progression of decline of renal function. However, due to methodological limitations of these studies further investigations are of urgent need to ensure the validity of this therapeutic concept.

Methods/Design

The SoBic-study is a single-center, randomized, controlled, open-label clinical phase IV study performed at the nephrological outpatient service of the Medical University of Vienna. Two-hundred patients classified to CKD stage 3 or 4 with two separate measurements of HCO₃^- of <21 mmol/L will be 1:1 randomized to either receive a high dose of oral sodium bicarbonate with a serum target HCO₃^- level of 24 ± 1 mmol/L or receive a rescue therapy of sodium bicarbonate with a serum target level of 20 ± 1 mmol/L. The follow up will be for two years. The primary outcome is the effect of sodium bicarbonate supplementation on renal function measured by means of estimated glomerular filtration rates (4-variable-MDRD-equation) after two years. Secondary outcomes are change in markers of bone metabolism between groups, death rates between groups, and the number of subjects proceeding to renal replacement therapy across groups. Adverse events, such as worsening of arterial hypertension due to the additional sodium consumption, will be accurately monitored.

Discussion

We hypothesize that sufficiently balanced acid–base homeostasis leads to a reduction of decline of renal function in patients with chronic kidney disease. The concept of an exogenous bicarbonate supplementation to substitute the lacking endogenous bicarbonate has existed for a long time, but has never been investigated sufficiently to state clear treatment guidelines.

Trial registration

EUDRACT Number: 2012-001824-36

【 授权许可】

   
2013 Gaggl et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870-878.
• [2]Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
• [3]Ruggenenti P, Perna A, Mosconi L, Matalone M, Garini G, Salvadori M, Zoccali C, Scolari F, Maggiore Q, Tognoni G, Remuzzi G: Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997, 349:1857-1863.
• [4]Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, Scolari F, Schena FP, Remuzzi G: Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999, 354:359-364.
• [5]Hostetter TH: Prevention of end-stage renal disease due to type 2 diabetes. N Engl J Med 2001, 345:910-912.
• [6]Appel LJ, Wright JT Jr, Greene T, Agodoa LY, Astor BC, Bakris GL, Cleveland WH, Charleston J, Contreras G, Faulkner ML, Gabbai FB, Gassman JJ, Hebert LA, Jamerson KA, Kopple JD, Kusek JW, Lash JP, Lea JP, Lewis JB, Lipkowitz MS, Massry SG, Miller ER, Norris K, Phillips RA, Pogue VA, Randall OS, Rostand SG, Smogorzewski MJ, Toto RD, Wang X: Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 2010, 363:918-929.
• [7]Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsarinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S: Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008, 372:547-553.
• [8]Tobe SW, Clase CM, Gao P, McQueen M, Grosshennig A, Wang X, Teo KK, Yusuf S, Mann JF: Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies. Circulation 2011, 123:1098-1107.
• [9]Ruggenenti P, Perna A, Tonelli M, Loriga G, Motterlini N, Rubis N, Ledda F, Rota S Jr, Satta A, Granata A, Battaglia G, Cambareri F, David S, Gaspari F, Stucchi N, Carminati S, Ene-Iordache B, Cravedi P, Remuzzi G: Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial. Clin J Am Soc Nephrol 2010, 5:1928-1938.
• [10]Klahr S, AS L, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G: The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of diet in renal disease study group. N Engl J Med 1994, 330:877-884.
• [11]Fink HA, Ishani A, Taylor BC, Greer NL, MacDonald R, Rossini D, Sadiq S, Lankireddy S, Kane RL, Wilt TJ: Screening for, monitoring, and treatment of chronic kidney disease stages 1 to 3: a systematic review for the U.S. Preventive services task force and for an American College of Physicians clinical practice guideline. Ann Intern Med 2012, 156:570-581.
• [12]Kopple JD, Kalantar-Zadeh K, Mehrotra R: Risks of chronic metabolic acidosis in patients with chronic kidney disease. Kidney Int 2005, 67(Suppl 95):21-27.
• [13]Lim VS, Yarasheski KE, Flanigan MJ: The effect of uraemia, acidosis, and dialysis treatment on protein metabolism: a longitudinal leucine kinetic study. Nephrol Dial Transplant 1998, 13:1723-1730.
• [14]Movilli E, Zani R, Carli O, Sangalli L, Pola A, Camerini C, Cancarini GC, Scolari F, Feller P, Maiorca R: Correction of metabolic acidosis increases serum albumin concentrations and decreases kinetically evaluated protein intake in haemodialysis patients: a prospective study. Nephrol Dial Transplant 1998, 13:1719-1722.
• [15]Kraut JA, Madias NE: Consequences and therapy of the metabolic acidosis of chronic kidney disease. Pediatr Nephrol 2011, 26:19-28.
• [16]Kraut JA, Kurtz I: Metabolic acidosis of CKD: diagnosis, clinical characteristics, and treatment. Am J Kidney Dis 2005, 45:978-993.
• [17]Wesson DE, Jo CH, Simoni J: Angiotensin II receptors mediate increased distal nephron acidification caused by acid retention. Kidney Int 2012, 82:1184-1194.
• [18]Gadola L, Noboa O, Marquez MN, Rodriguez MJ, Nin N, Boggia J, Ferreiro A, Garcia S, Ortega V, Musto ML, Ponte P, Sesser P, Pizarrosa C, Ravaglio S, Vallega A: Calcium citrate ameliorates the progression of chronic renal injury. Kidney Int 2004, 65:1224-1230.
• [19]Jara A, Felsenfeld AJ, Bover J, Kleeman CR: Chronic metabolic acidosis in azotemic rats on a high-phosphate diet halts the progression of renal disease. Kidney Int 2000, 58:1023-1032.
• [20]Wesson DE, Simoni J: Acid retention during kidney failure induces endothelin and aldosterone production which lead to progressive GFR decline, a situation ameliorated by alkali diet. Kidney Int 2010, 78:1128-1135.
• [21]Nath KA, Hostetter MK, Hostetter TH: Pathophysiology of chronic tubulo-interstitial disease in rats. Interactions of dietary acid load, ammonia, and complement component C3. J Clin Invest 1985, 76:667-675.
• [22]Phisitkul S, Hacker C, Simoni J, Tran RM, Wesson DE: Dietary protein causes a decline in the glomerular filtration rate of the remnant kidney mediated by metabolic acidosis and endothelin receptors. Kidney Int 2008, 73:192-199.
• [23]Kovesdy CP, Anderson JE, Kalantar-Zadeh K: Association of serum bicarbonate levels with mortality in patients with non-dialysis-dependent CKD. Nephrol Dial Transplant 2009, 24:1232-1237.
• [24]Shah SN, Abramowitz M, Hostetter TH, Melamed ML: Serum bicarbonate levels and the progression of kidney disease: a cohort study. Am J Kidney Dis 2009, 54:270-277.
• [25]Navaneethan SD, Schold JD, Arrigain S, Jolly SE, Wehbe E, Raina R, Simon JF, Srinivas TR, Jain A, Schreiber MJ Jr, Nally JV Jr: Serum Bicarbonate and Mortality in Stage 3 and Stage 4 Chronic Kidney Disease. Clin J Am Soc Nephrol 2011, 6:2395-2402.
• [26]Mahajan A, Simoni J, Sheather SJ, Broglio KR, Rajab MH, Wesson DE: Daily oral sodium bicarbonate preserves glomerular filtration rate by slowing its decline in early hypertensive nephropathy. Kidney Int 2010, 78:303-309.
• [27]Phisitkul S, Khanna A, Simoni J, Broglio K, Sheather S, Rajab MH, Wesson DE: Amelioration of metabolic acidosis in patients with low GFR reduced kidney endothelin production and kidney injury, and better preserved GFR. Kidney Int 2010, 77:617-623.
• [28]de Brito-Ashurst I, Varagunam M, Raftery MJ, Yaqoob MM: Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol 2009, 20:2075-2084.
• [29]WMA: WMA declaration of Helsinki - Ethical principles for medical research involving human subjects.   2008. http://www.wma.net/en/30publications/10policies/b3/index.html webcite
• [30]EMEA: Guideline for good clinical practice ICH topic E 2002, 6, Step 5.  http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002874.pdf webcite
• [31]Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG: CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol 2010, 2010:e1-e37.
• [32]Liamis G, Milionis HJ, Elisaf M: Pharmacologically-induced metabolic acidosis: a review. Drug Saf 2010, 33:371-391.
• [33]Cejka D, Jager-Lansky A, Kieweg H, Weber M, Bieglmayer C, Haider DG, Diarra D, Patsch JM, Kainberger F, Bohle B, Haas M: Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients. Nephrol Dial Transplant 2012, 27:226-230.
• [34]Frassetto LA, Morris RC Jr, Sebastian A: Effect of age on blood acid–base composition in adult humans: role of age-related renal functional decline. Am J Physiol 1996, 271:F1114-F1122.
• [35]Caravaca F, Arrobas M, Pizarro JL, Esparrago JF: Metabolic acidosis in advanced renal failure: differences between diabetic and nondiabetic patients. Am J Kidney Dis 1999, 33:892-898.
• [36]Manjunath G, Sarnak MJ, Levey AS: Prediction equations to estimate glomerular filtration rate: an update. Curr Opin Nephrol Hypertens 2001, 10:785-792.
• [37]Rizopulos DJ: An R Package for the joint modelling of longitudinal and time-to-event data. J Stat Software 2010, 35:1-33.
• [38]Fine J, Gray R: A Proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999, 94:496-509.
• [39]Lyon MD, Dunlop DM, Stewart CP: The alkaline treatment of chronic nephritis. Lancet 1931, 2:1009-1013.
• [40]Sahni V, Rosa RM, Batlle D: Potential benefits of alkali therapy to prevent GFR loss: time for a palatable ‘solution’ for the management of CKD. Kidney Int 2010, 78:1065-1067.
• [41]Abboud H, Henrich WL: Clinical practice. Stage IV chronic kidney disease. N Engl J Med 2010, 362:56-65.
• [42]Frassetto LA, Hsu CY: Metabolic acidosis and progression of chronic kidney disease. J Am Soc Nephrol 2009, 20:1869-1870.
• [43]John R, Webb M, Young A, et al.: Unreferred chronic kidney disease: a longitudinal study. Am J Kidney Dis 2004, 43:825-835.
• [44]Conway B, Webster A, Ramsay G, Morgan N, Neary J, Whitworth C, Harty J: Predicting mortality and uptake of renal replacement therapy in patients with stage 4 chronic kidney disease. Nephrol Dial Transplant 2009, 24:1930-1937.
• [45]Levin A, Djurdjev O, Beaulieu M, Er L: Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort. Am J Kidney Dis 2008, 52:661-671.
• [46]Holland DC, Lam M: Predictors of hospitalization and death among pre-dialysis patients: a retrospective cohort study. Nephrol Dial Transplant 2000, 15:650-658.
• [47]Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004, 351:1296-1305.
• [48]Agarwal R, Bunaye Z, Bekele DM, Light RP: Competing risk factor analysis of end-stage renal disease and mortality in chronic kidney disease. Am J Nephrol 2008, 28:569-575.
• [49]Nolan CR, Califano JR, Butzin CA: Influence of calcium acetate or calcium citrate on intestinal aluminum absorption. Kidney Int 1990, 38:937-941.
• [50]Goraya N, Simoni J, Jo C, Wesson DE: Dietary acid reduction with fruits and vegetables or bicarbonate attenuates kidney injury in patients with a moderately reduced glomerular filtration rate due to hypertensive nephropathy. Kidney Int 2012, 81:86-93.
• [51]Krishnamurthy VM, Wei G, Baird BC, Murtaugh M, Chonchol MB, Raphael KL, Greene T, Beddhu S: High dietary fiber intake is associated with decreased inflammation and all-cause mortality in patients with chronic kidney disease. Kidney Int 2012, 81:300-306.
• [52]Goraya N, Wesson DE: Acid–base status and progression of chronic kidney disease. Curr Opin Nephrol Hypertens 2012, 21:552-556.
• [53]Whitescarver SA, Ott CE, Jackson BA, Guthrie GP Jr, Kotchen TA: Salt-sensitive hypertension: contribution of chloride. Science 1984, 223:1430-1432.
• [54]Kurtz TW, Al-Bander HA Jr, Morris RC: “Salt-sensitive” essential hypertension in men. Is the sodium ion alone important? N Engl J Med 1987, 317:1043-1048.
• [55]Shore AC, Markandu ND, MacGregor GA: A randomized crossover study to compare the blood pressure response to sodium loading with and without chloride in patients with essential hypertension. J Hypertens 1988, 6:613-617.
• [56]de Solis AJ, Gonzales-Pacheco FR, Deudero JJ, Neria F, Albalate M, Petkov V, Susanibar L, Fernandez-Sanchez R, Calabia O, Ortiz A, Caramelo C: Alkalinization potentiates vascular calcium deposition in an uremic milieu. J Nephrol 2009, 22:647-653.